Employees: 508
Size Nanosonics (NAN.AX) is an Australia Health Care company (Medical Specialties) with a market value of $599M, the 232nd largest of 317 Australia companies the cockpit tracks. Shares closed at A$2.96 on 18 Nov 2026.
Performance Over six months the shares fell 4.2%, against -20.3% for the median peer and +1.2% for the Australia market (cap-weighted) — 9th highest of 19 in its peer set.
Growth Revenue grew 2.6% over the last twelve months (peer median +16.1%); the operating margin is 7.4% (peer median 8.5%).
Valuation It trades at 98.6× forward earnings against a peer median of 20.0× (most expensive of 13).
Price implies For today's price to make sense, revenue must grow about 35% a year for seven years (Req g). Recent delivered growth is +7%, so the hurdle is +29 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 1.5 points above its cost of capital (10.8% WACC).
Next results Next results expected around 23 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2026 | FY2025 | FY2024 | FY2023 | |
|---|---|---|---|---|---|
| Revenue | A$203M | A$203M | A$198M | A$172M | A$168M |
| Revenue growth | — | +3% | +16% | +2% | — |
| Gross profit | A$156M | A$149M | A$148M | A$127M | A$126M |
| EBITDA | A$23.7M | A$23.7M | A$24.5M | A$16.0M | A$25.1M |
| Net income | A$17.8M | A$17.8M | A$20.7M | A$13.0M | A$19.9M |
| Free cash flow | A$17.4M | A$17.4M | A$35.3M | A$20.3M | A$19.7M |
| Capital expenditure | A$5.14M | A$5.14M | A$8.72M | A$2.52M | A$3.57M |
| Total debt | n/a | A$23.1M | A$7.69M | A$9.30M | A$10.7M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | NAN.AX | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -1.3% | -5.5% | 8th highest of 19 |
| 6-month return | -4.2% | -20.3% | 9th highest of 19 |
| Distance from 52-week high | -32.7% | -34.3% | 10th highest of 20 |
| Revenue growth (TTM) | +2.6% | +16.1% | 6th lowest of 20 |
| Operating margin | 7.4% | 8.5% | 9th lowest of 20 |
| Forward P/E | 98.6× | 20.0× | most expensive of 13 |
| Growth the price implies (Req g, 7 yrs) | 35.3% | 0.3% | 2nd most demanding of 11 |
| Growth delivered (Del g) | +6.7% | +13.2% | 5th lowest of 11 |
| Hurdle (Req g minus delivered) | +28.6 pp | -13.2 pp | 2nd most demanding of 11 |
| ROIC minus cost of capital | +1.5 pp | +0.3 pp | 10th highest of 19 |
| EV / EBITDA | 32.2× | 13.2× | most expensive of 8 |
| Net debt / EBITDA | -5.6× | -0.7× | least indebted of 8 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Nanosonics NAN.AX | Australia | $599M | -4% | +3% | 7% | 98.6× | 35.3% | +6.7% |
| Medistim MEDI.OL | Norway | $599M | +32% | +19% | 29% | 31.8× | -1.2% | +14.5% |
| Sight Sciences SGHT | United States | $599M | +122% | +16% | -30% | n/a | n/a | n/a |
| Sahajanand Medical Technologies SMT.NS | India | $595M | n/a | n/a | n/a | n/a | n/a | n/a |
| vVARDIS VVVV | United States | $594M | n/a | +148% | -72% | n/a | n/a | n/a |
| Tactile Systems Technology TCMD | United States | $592M | +6% | +14% | 9% | 21.1× | 8.4% | +12.0% |
| Hangzhou AGS MedTech 688581.SS | China | $590M | -22% | -18% | 33% | 18.9× | 0.4% | +27.8% |
| Ningbo David Medical Device 300314.SZ | China | $589M | +25% | +19% | 11% | 12.0× | n/a | n/a |
| Orchestra BioMed OBIO | United States | $587M | +87% | +1,007% | -195% | n/a | n/a | n/a |
| Xvivo Perfusion XVIVO.ST | Sweden | $611M | -32% | +18% | 12% | 53.1× | 35.9% | +35.2% |
| Beijing Chunlizhengda Medical Instruments 688236.SS | China | $618M | -27% | -13% | 31% | 17.4× | -8.5% | +2.2% |
| Jiangsu Hanvo Safety Product 300952.SZ | China | $575M | -38% | +6% | 8% | 39.7× | n/a | n/a |
| Pacific Biosciences of California PACB | United States | $573M | +54% | +4% | -98% | n/a | n/a | n/a |
| SunMax Biotechnology 4728.TWO | Taiwan | $630M | 0% | +19% | 51% | n/a | -2.6% | +18.8% |
| Wuhan Huakang Century Clean Technology 301235.SZ | China | $563M | -57% | +28% | 7% | 33.7× | n/a | n/a |
| Cowealth Medical China 603122.SS | China | $562M | -34% | -18% | -5% | n/a | n/a | n/a |
| AK Medical 1789.HK | Hong Kong | $642M | -23% | +16% | 26% | 10.5× | -11.5% | +6.7% |
| Contec Medical Systems 300869.SZ | China | $547M | -26% | -2% | -16% | n/a | 15.0% | -19.8% |
| QuidelOrtho QDEL | United States | $657M | -20% | -5% | -2% | 10.7× | n/a | n/a |
| Zhejiang Gongdong Medical Technology 605369.SS | China | $542M | -21% | +6% | 9% | 23.5× | 10.2% | +6.5% |
| Synektik SNT.WA | Poland | $662M | +10% | +32% | 24% | 13.8× | 0.2% | +47.5% |